01Mar 2025
MAIA Study: D-Rd Improves Survival in Transplant-Ineligible NDMM Patients

MAIA Study: D-Rd Improves Survival in Transplant-Ineligible NDMM Patients

In the MAIA study (64.5-month follow-up), D-Rd extended PFS (61.9 vs. 34.4 months; HR 0.55) and OS (not reached vs. 65.5 months; HR 0.66) over Rd. D-Rd also increased ≥CR rates (51.1% vs. 30.1%) and MRD negativity (32.1% vs. 11.1%). Benefits were consistent across age groups, with no new safety concerns. The findings reinforce D-Rd as a frontline NDMM therapy.

  • #oncology

Like

Save

Share